Acute coronary syndromes (ACS) involve high mortality risk, especially ST elevation ACS. Their treatment is based on reperfusion, dual antiplatelet therapy (DAPT) and anticoagulation, with enoxaparin (1 mg/kg twice a day) as the preferred anticoagulant according to the contemporary guidelines. 2.5 mg or 5 mg doses of rivaroxaban might be valid alternative treatments for this<a href="https://solaci.org/en/2023/02/23/rivaroxaban-in-acute-coronary-syndrome/" title="Read more" >...</a>
Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the rate of restenosis in obstructive femoropopliteal lesions compared with conventional balloons or conventional stents (bare-nitinol stent, BNS). Both in the placement of BNS and of drug-eluting stents (DES) there is a mechanical risk of stent fracture or<a href="https://solaci.org/en/2023/02/22/arterial-patency-in-femoropopliteal-disease-with-drug-eluting-balloons/" title="Read more" >...</a>
This study compared fractional flow reserve (FFR) vs. angiography to guide the angioplasty of non-culprit vessels in patients with acute coronary syndrome (ACS) and multivessel disease. Landmark studies such as COMPLETE, COMPARE-ACUTE and DANAMI-3-PRIMULTI have demonstrated the prognostic value of revascularization (after treatment of the artery responsible for the ACS) of non-culprit arteries with respect<a href="https://solaci.org/en/2023/01/25/frame-ami-ffr-vs-angiography-of-non-culprit-vessel-in-acs/" title="Read more" >...</a>
Currently, myocardial revascularization surgery (MRS) and percutaneous coronary intervention (PCI) are the available strategies for multivessel coronary artery disease. However, an alternative strategy has long been developed, called hybrid coronary revascularization (HCR), where the anterior descending artery is bypassed with a graft from the mammary artery and the rest of the lesions are treated by<a href="https://solaci.org/en/2023/01/23/long-term-evolution-of-hybrid-coronary-revascularization/" title="Read more" >...</a>
In this article, we will examine the use of hybrid coronary revascularization to treat multivessel coronary artery disease. Coronary artery disease (CAD) is the most common cause of morbidity and mortality in the western world. The presence of multivessel CAD is associated to high short and midterm mortality and coronary artery bypass graft (CABG) is<a href="https://solaci.org/en/2023/01/12/hybrid-coronary-revascularization-a-valid-option/" title="Read more" >...</a>
Revascularization and antiaggregation guidelines have typically recommended aspirin (AAS) as first choice for secondary prevention of cardiovascular events after DES stenting. However, these past few years this strategy has been called into question, seeing as studies have shown the superiority of P2Y12 inhibitor monotherapy (IP2Y12) with clopidogrel or ticagrelor. There is little data comparing both<a href="https://solaci.org/en/2022/12/05/p2y12-inhibitor-monotherapy-vs-aspirin-results-of-a-network-meta-analysis/" title="Read more" >...</a>
Much research has been done on the usefulness of functional testing such as fractional Flow reserve (FFR) after percutaneous coronary intervention (PCI), resulting in the correlation of pathological FFR values with major adverse events at 6 months, as shown by Pijls, et al. The impact of post PCI FFR on prognosis has not been studied<a href="https://solaci.org/en/2022/11/30/post-pci-ffr/" title="Read more" >...</a>
During SOLACI-SOCIME 2022, our traditional education program for young interventionists ProEducar Fellows Course was held. Discover the presentations of the prestigious interventionists that made part of this 12th edition here below. Dr. Leandro Lasave (ARG) – “Transradial access: When and how? Practical lesson for access without complications” PRESENTATION Dr. Alejandro Alcocer (MEX) – “Practical demonstration of aortic<a href="https://solaci.org/en/2022/11/21/see-the-presentations-of-the-12th-proeducar-fellows-course/" title="Read more" >...</a>
Many randomized studies and systematic revisions have shown that an early invasive approach (within 24hrs. after diagnosis) will not reduce mortality across the non-ST elevation acute coronary syndrome (NST-ACS) population, hence the relevance of NST-ACS; patients with a GRACE score higher than 140 were the ones showing improved outcomes. Roughly 40% of NST-ACS patients have<a href="https://solaci.org/en/2022/10/24/early-invasive-strategy-for-non-st-elevation-acs-in-chronic-kidney-disease/" title="Read more" >...</a>
Severely calcified coronary lesions are found in 25% of patients undergoing PCI, and their presence has a negative impact in long term outcomes. These lesions difficult stent expansion and increase device failure rate, even when using the latest generation of drug eluting stents (DES). This is why there is an interest in lesion preparation strategies<a href="https://solaci.org/en/2022/09/28/devices-to-prepare-severely-calcified-lesions-is-there-a-difference-when-assessed-by-intravascular-imaging/" title="Read more" >...</a>